© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 09, 2015, the consensus forecast amongst 20 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 14, 2015. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 19 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,870, with a high estimate of 2,200 and a low estimate of 1,090. The median estimate represents a 1.63% increase from the last price of 1,840. View Full Financials
In 2014, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, which represents a 11.76% increase over last year. The 16 analysts covering the company expect dividends of 22.36 IDR for the upcoming fiscal year, an increase of 17.66%. View Full Financials
|Div growth (TTM)||+11.76 %|
On Jul 25, 2014, Kalbe Farma Tbk PT reported 2nd quarter 2014 earnings of 10.00 per share. This result under-performed the 11.97 expectation of the one analyst following the company but was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Jul 23, 2015. View Full Interim Financials
|Average growth rate||+1.48 %|
Kalbe Farma Tbk PT reported annual 2014 earnings of 44.00 per share on Mar 30, 2015. View Full Annual Financials
|Average growth rate||+12.64 %|
PT Kalbe Farma Tbk had 1st quarter 2015 revenues of 4.2467bn. This missed the 4.4966bn estimate of the one analyst following the company. This was 7.88 % below the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+1.25 %|
PT Kalbe Farma Tbk had revenues for the full year 2014 of 17.3685bn. This was 8.54% above the prior year's results. View Full Annual Financials
|Average growth rate||+14.39 %|